

05 November 2025

Option exercised to advance acquisition of Stabl-Im technology for the early and safe detection of brain tumours

Highlights:

- **Company exercises Option to acquire Stabl-Im™ metastatic brain imaging technology following completion of detailed due diligence**
- **Technology has the potential to enable safe, non-invasive imaging and monitoring of brain cancers through stable isotope labelling detectable by MRI, targeting early identification of proliferating tumour cells**
- **Brain metastases affect up to 20% of adult cancer patients with very limited treatment options and life expectancy for patients with advanced disease**
- **Acquisition pending shareholder approval at a general meeting expected to be held in mid-December 2025**
- **Following shareholder approval, TrivarX plans to commence its near-term work program which includes manufacturing and quality-control validation, regulatory engagement with the FDA and EU authorities, and initiation of a Phase 1 clinical trial in CY26**

Perth, Australia, and Minneapolis, USA: TrivarX Limited (“the Company”) (ASX: TRI) is pleased to advise it has exercised its Option to acquire all intellectual property associated with the novel brain imaging technology Stabl-Im™ (‘Stabl-Im’) from Nucleics Pty Ltd (‘Nucleics’) (refer ASX announcement: 16 October 2025).

The exercise follows extensive due diligence undertaken by the Company which has provided confidence in Stabl-Im and its potential as a safe and non-invasive imaging agent for brain cancers and metastases.

Stabl-Im uses stable isotope labelling to detect proliferating tumour cells or regions of active tumour growth through MRI, enabling early and non-invasive visualisation of tumour activity without radiation or surgery. This approach targets a major unmet need in brain cancer diagnostics, where current MRI methods only detect tumours once they reach 2mm to 3mm in size. By enabling the earlier indication of tumour activity, Stabl-Im has the potential to transform brain cancer detection and monitoring, providing clinicians with a safe, repeatable method to guide treatment decisions.

Completion of the acquisition is subject to shareholder approval at a general meeting, which is expected to be held in mid-December 2025. Should shareholder approval be granted, TrivarX will then commence its near-term work program alongside Nucleics, which includes manufacturing and quality-control validation of isotope imaging compounds, pre-submission engagement with the FDA and EU regulatory agencies, and detailed clinical study design to assess safety and imaging precision. This will be followed by commencement of a Phase 1 clinical trial in CY26.

For personal use only

ASX ANNOUNCEMENT



Commentary:

Non-executive Chairman, David Trimboli said: *“The execution of this Option is an exciting step forward for the Company as we expand our diagnostic portfolio into oncology. The proposed acquisition of Stabl-Im builds directly on our core mission to develop safe, non-invasive technologies that improve early disease detection and clinical-decision making.*

Stabl-Im represents a potential paradigm shift in brain cancer imaging, with the potential to identify tumour activity long before conventional methods. This technology complements our existing neurodiagnostic programs and positions the Company at the forefront of precision imaging. We look forward to the pending general meeting to seek shareholder approval and then working with Dr Tillett and the Nucleics team as we advance the next phase of development.”

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au

For personal use only